Pharma Focus Asia
KP - Sustainable Packaging Solutions

Kite Announces Plans to Build a New Manufacturing Industry


Kite announces plans to build industry-leading cell therapy manufacturing capabilities with a new viral vector facility in Oceanside, California.


A new state-of-the-art 67,000 square feet building will be constructed inside Gilead’s existing facility.

The new facility will manufacture the viral vectors such as replication-deficient gamma-retroviral vector PG13-CD19-H3 and replication-deficient lentiviral vector.

PG13-CD19-H3 is the important initial material used for production of Yescarta. It was the company’s first Chimeric Antigen Receptor (CAR) T-cell therapy that is used for treatment of large B-cell lymphoma in adult patients.

Yescarta extracts white blood cells (WBCs) from the patient's body and differentiate T-cells from the WBCs to modify and re-use them into patient's body to identify and kill the cancer cells.

The retroviral vector PG13-CD19-H3 is also used for development of other investigational therapies such as KTE-X19 for acute lymphocytic leukaemia and mantle cell lymphoma. The facility also supports the investigational biologic production of KITE-585 and KITE-718 therapy.


NameKite, a Gilead Company
LocationOceanside, California, USA
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?